Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(15)70208-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune Checkpoints and Their Inhibition in T-Cell Lymphomas.
Folia Biol (Praha)
December 2024
1st Department of Medicine - Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
T-cell lymphomas (TCLs) are a rare and heterogeneous subgroup of non-Hodgkin lymphomas (NHLs), forming only 10 % of all NHL cases in Western countries. Resulting from their low incidence and heterogeneity, the current treatment outcome is generally unfavorable, with limited availability of novel therapeutic approaches. Therefore, the recent success of immune checkpoint inhibitors (ICIs) in cancer treatment motivated their clinical investigation in TCLs as well.
View Article and Find Full Text PDFAnti-PD-L1 Antibody Fragment Linked to Tumor-Targeting Lipid Nanoparticle Can Eliminate Cancer and Its Metastasis via Photoimmunotherapy.
ACS Nano
December 2024
Department of Microbiology, Brain Korea 21 Project, University of Ulsan College of Medicine, ASAN Medical Center, Seoul 05505, South Korea.
Effective cancer therapy aims to treat primary tumors and metastatic and recurrent cancer. Immune checkpoint blockade-mediated immunotherapy has shown promising effects against tumors; however, its efficacy in metastatic or recurrent cancer is limited. Here, based on the advantages of nanomedicine, lipid nanoparticles (LNPs) that can target tumors are synthesized for photothermal therapy (PTT) and immunotherapy to treat primary and metastatic recurrent cancer.
View Article and Find Full Text PDFLocal Exosome Inhibition Potentiates Mild Photothermal Immunotherapy Against Breast Cancer.
Adv Sci (Weinh)
November 2024
State Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China.
Article Synopsis
- Limited immune cell presence in tumors reduces the effectiveness of immune checkpoint blockade (ICB) therapy, leading researchers to combine it with mild photothermal therapy (PTT) to improve immune response.
- Bioinformatics studies show that mild PTT increases immune cell infiltration and T-cell activity while also promoting the release of tumor-derived exosomes and raising PD-L1 expression on tumor cells.
- A new multi-stage drug delivery system is created to deliver photosensitizers, anti-PD-L1 antibodies, and exosome inhibitors, using temperature-sensitive materials to improve therapeutic outcomes and reshape the tumor microenvironment for better response against "cold" tumors.
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors.
J Immunother Cancer
November 2024
Early Drug Development, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: MEDI5395 is a recombinant attenuated Newcastle disease virus engineered to express a human granulocyte-macrophage colony-stimulating factor transgene. Preclinically, MEDI5395 demonstrated broad oncolytic activity, augmented by concomitant programmed cell death-1/programmed cell death ligand-1 (PD-L1) axis blockade. Durvalumab is an anti-PD-L1 immune checkpoint inhibitor approved for the treatment of various solid tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!